Genetic variants associated with psychotic symptoms across psychiatric disorders.


Journal

Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130

Informations de publication

Date de publication:
16 02 2020
Historique:
received: 19 09 2019
revised: 06 12 2019
accepted: 11 01 2020
pubmed: 17 1 2020
medline: 17 4 2021
entrez: 17 1 2020
Statut: ppublish

Résumé

Recent evidence suggests that psychiatric symptoms share a common genetic liability across diagnostic categories. The present study investigated the effects of variants within previously identified relevant genes on specific symptom clusters, independently from the diagnosis. 1550 subjects affected by Schizophrenia (SCZ), Major Depressive Disorder or Bipolar Disorder were included. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale (HDRS). Principal component analysis and a further clinical refinement were used to define symptom clusters. Clusters scores were tested for association with 46 genetic variants within nine genes previously linked to one or more major psychiatric disorders by large genome wide association studies (ANK3, CACNA1C, CACNB2, FKBP5, FZD3, GRM7, ITIH3, SYNE1, TCF4). Exploratory analyses were performed in each disorder separately to further elucidate the SNPs effects. five PANSS clusters (Negative; Impulsiveness; Cognitive; Psychotic; Depressive) and four HDRS clusters (Core Depressive; Somatic; Psychotic-like; Insomnia) were identified. CACNA1C rs11615998 was associated with HDRS Psychotic cluster in the whole sample. In the SCZ sample, CACNA1C rs11062296 was associated with PANSS Impulsiveness cluster and CACNA1C rs2238062 was associated with PANSS negative cluster. CACNA1C rs11615998 was associated with psychotic symptoms (C-allele carriers have decreased psychotic-risk) independently from the diagnosis, in line with the evidence of a cross disorder effect of many risk variants. This gene was previously associated with SCZ and cross-disorder liability to psychiatric disorders. Our findings confirmed that deep phenotyping is pivotal to clarify the role of genetic variants on symptoms patterns.

Sections du résumé

BACKGROUND
Recent evidence suggests that psychiatric symptoms share a common genetic liability across diagnostic categories. The present study investigated the effects of variants within previously identified relevant genes on specific symptom clusters, independently from the diagnosis.
METHODS
1550 subjects affected by Schizophrenia (SCZ), Major Depressive Disorder or Bipolar Disorder were included. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale (HDRS). Principal component analysis and a further clinical refinement were used to define symptom clusters. Clusters scores were tested for association with 46 genetic variants within nine genes previously linked to one or more major psychiatric disorders by large genome wide association studies (ANK3, CACNA1C, CACNB2, FKBP5, FZD3, GRM7, ITIH3, SYNE1, TCF4). Exploratory analyses were performed in each disorder separately to further elucidate the SNPs effects.
RESULTS
five PANSS clusters (Negative; Impulsiveness; Cognitive; Psychotic; Depressive) and four HDRS clusters (Core Depressive; Somatic; Psychotic-like; Insomnia) were identified. CACNA1C rs11615998 was associated with HDRS Psychotic cluster in the whole sample. In the SCZ sample, CACNA1C rs11062296 was associated with PANSS Impulsiveness cluster and CACNA1C rs2238062 was associated with PANSS negative cluster.
DISCUSSION
CACNA1C rs11615998 was associated with psychotic symptoms (C-allele carriers have decreased psychotic-risk) independently from the diagnosis, in line with the evidence of a cross disorder effect of many risk variants. This gene was previously associated with SCZ and cross-disorder liability to psychiatric disorders. Our findings confirmed that deep phenotyping is pivotal to clarify the role of genetic variants on symptoms patterns.

Identifiants

pubmed: 31945448
pii: S0304-3940(20)30024-0
doi: 10.1016/j.neulet.2020.134754
pii:
doi:

Substances chimiques

CACNA1C protein, human 0
Calcium Channels, L-Type 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

134754

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Marco Calabrò (M)

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy.

Stefano Porcelli (S)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.

Concetta Crisafulli (C)

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy.

Diego Albani (D)

Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

Siegfried Kasper (S)

Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria.

Joseph Zohar (J)

Department of Psychiatry, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel.

Daniel Souery (D)

Laboratoire de Psychologie Medicale, Universitè Libre de Bruxelles and Psy Pluriel, Centre Européen de Psychologie Medicale, Brussels, Belgium.

Stuart Montgomery (S)

lmperial College School of Medicine, London, UK.

Vilma Mantovani (V)

Center for Applied Biomedical Research (CRBA), St. Orsola University Hospital, Bologna, Italy.

Julien Mendlewicz (J)

Université Libre de Bruxelles, Belgium.

Stefano Bonassi (S)

Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana, Rome, Italy; Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy.

Eduard Vieta (E)

Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.

Alessandra Frustaci (A)

Barnet, Enfield and Haringey Mental Health NHS Trust, St.Ann's Hospital, St.Ann's Road, N15 3 TH, London, UK.

Giuseppe Ducci (G)

Mental Health Department, ASL Roma 1, Rome, Italy.

Stefano Landi (S)

Dipartimento di Biologia, Università di Pisa, Pisa, Italy.

Stefania Boccia (S)

Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italy; Department of Woman and Child Health and Public Health - Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Antonello Bellomo (A)

Dipartimento di Medicina Clinica e Sperimentale, Foggia University, Italy.

Marco Di Nicola (M)

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Luigi Janiri (L)

Faculty of Medicine "Agostino Gemelli", Catholic University of the Sacred Heart, Rome, Italy.

Roberto Colombo (R)

Division of Neuroscience, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy.

Francesco Benedetti (F)

Faculty of Medicine "Agostino Gemelli", Catholic University of the Sacred Heart, Rome, Italy.

Laura Mandelli (L)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.

Chiara Fabbri (C)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.

Alessandro Serretti (A)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy. Electronic address: alessandro.serretti@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH